CD20
43 programs · 41 companies
Programs
43
Companies
41
Active Trials
21
Targeting CD20
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | Celiac | |
| Lisolucimab | Novartis | Approved | Narcolepsy | |
| ABB-8985 | AbbVie | Phase 2 | PVPAH | |
| ARG-3265 | Argenx | Phase 1/2 | MM | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | Ovarian CaAlzheimer's | |
| AKR-4818 | Akero | Approved | Urothelial CaHeart Failure | |
| Peminaritide | iTeos | NDA/BLA | CKDBCC | |
| Rimatinib | Ventyx Bio | Phase 1 | PompeUrothelial Ca | |
| Lisozanubrutinib | Poseida | NDA/BLA | Cervical CaHeart Failure | |
| INS-6048 | Insilico Medicine | NDA/BLA | Hemophilia A | |
| AVX-9264 | Anavex | Phase 2/3 | ADPKDNSCLC | |
| REP-2935 | Replimune | Approved | OCD | |
| Gozenesiran | Aligos | NDA/BLA | MG | |
| INH-3643 | Inhibrx (Sanofi) | NDA/BLA | AngelmanWM | |
| CON-4833 | ContraFect (Phibro) | Phase 2/3 | SMACF | |
| Adagranaritide | Imago BioSciences | Phase 2 | PSPFTD | |
| CRN-1592 | Crinetics Pharma | Phase 1/2 | EpilepsyAngelman | |
| TAR-1794 | Taro Pharma | NDA/BLA | ObesityCSU | |
| Zenonesiran | Cidara Therapeutics | Preclinical | HCCCTCL | |
| SCI-9093 | Sciwind Bio | Phase 1/2 | GIST | |
| Ribotinib | Sciwind Bio | Phase 1/2 | CFMeso | |
| Nirasertib | Loxo (Lilly) | Phase 2 | DMDPsoriasis | |
| Mirilemzoparlimab | Allergan (AbbVie) | Phase 2 | MDDGA | |
| Gozemavacamten | Dermira (Lilly) | Approved | Cervical CaAlzheimer's | |
| CLS-4466 | Clearside Bio | NDA/BLA | RA | |
| DUK-IIT-634 | Duke Cancer | Approved | Schizophrenia | |
| Adagraderotide | Oncolytics Bio | Phase 2 | MGCSU | |
| Olpacagene | Frontier Med | NDA/BLA | MSMyelofibrosis | |
| Lisonaritide | Hansa Bio | Preclinical | RAWM | |
| SPR-5098 | Sprint Bio | Phase 2 | PV | |
| IMT-6167 | Immatics | Phase 1 | Parkinson'sPancreatic Ca | |
| GRF-8988 | Grifols SA | Phase 2/3 | Heart Failure | |
| FYB-7121 | Formycon | Phase 1/2 | AML | |
| SLN-2895 | Silence Therapeutics | Preclinical | Pancreatic CaCSU | |
| Niratinib | Servier | Preclinical | CML | |
| Sovasertib | Granules India | Phase 2 | SchizophreniaGastric Ca | |
| JUB-6215 | Jubilant Pharmova | Phase 2/3 | EpilepsyOCD | |
| TEV-8109 | Teva Pharma | Phase 1 | Gastric CaHCC | |
| PET-IIT-178 | Peter MacCallum | Phase 3 | Ovarian Ca | |
| PET-IIT-588 | Peter MacCallum | Phase 2 | RA | |
| KIN-IIT-556 | King Faisal Spec Hosp | Approved | Pompe | |
| ATA-3814 | atai Life Sciences | NDA/BLA | HCCPompe | |
| VCY-7974 | Veracyte | Phase 1 | ThymomaEoE |